1.28
前日終値:
$1.24
開ける:
$1.265
24時間の取引高:
518.94K
Relative Volume:
0.28
時価総額:
$146.69M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.7758
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
+13.27%
1か月 パフォーマンス:
+12.28%
6か月 パフォーマンス:
-4.48%
1年 パフォーマンス:
-77.02%
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
FATE
Fate Therapeutics Inc
|
1.28 | 142.14M | 13.45M | -178.23M | -132.53M | -1.65 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
2023-01-06 | ダウングレード | Stifel | Buy → Hold |
2023-01-06 | ダウングレード | Truist | Buy → Hold |
2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
2022-12-15 | 開始されました | Goldman | Sell |
2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
2022-10-10 | 開始されました | Canaccord Genuity | Buy |
2022-08-18 | 再開されました | Wells Fargo | Overweight |
2022-07-28 | 開始されました | Needham | Hold |
2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2022-06-03 | 開始されました | Robert W. Baird | Neutral |
2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
2021-12-07 | 開始されました | Cowen | Outperform |
2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
2021-04-26 | 再開されました | Jefferies | Buy |
2021-02-26 | 開始されました | BofA Securities | Buy |
2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
2020-05-13 | 開始されました | H.C. Wainwright | Buy |
2020-03-04 | 開始されました | Barclays | Overweight |
2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2019-12-30 | 繰り返されました | Mizuho | Buy |
2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
2019-11-12 | 開始されました | SunTrust | Buy |
2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
2019-10-01 | 開始されました | Stifel | Buy |
2019-08-09 | 開始されました | BTIG Research | Buy |
2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
2019-07-12 | 開始されました | Oppenheimer | Outperform |
2019-06-13 | 開始されました | Mizuho | Buy |
2019-06-07 | 開始されました | ROTH Capital | Neutral |
2019-05-31 | 開始されました | Guggenheim | Buy |
2019-05-24 | 再開されました | Citigroup | Buy |
2019-03-28 | 開始されました | SVB Leerink | Outperform |
2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
2018-11-05 | 開始されました | Jefferies | Buy |
2018-08-01 | 開始されました | Citigroup | Buy |
2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
What analysts say about Fate Therapeutics Inc. stockSkyrocketing investment returns - jammulinksnews.com
Is Fate Therapeutics Inc. a good long term investmentExceptional gains - Autocar Professional
Fate Therapeutics Inc. Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com
What drives Fate Therapeutics Inc. stock priceUnstoppable trading performance - Autocar Professional
why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser
what makes fate therapeutics inc. stock price move sharplyIntraday Trade Ideas - Newser
Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - MSN
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of “Hold” from Brokerages - Defense World
How Fate Therapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser
Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
What makes Fate Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully - Yahoo Finance
10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey
Research Analysts Offer Predictions for FATE Q2 Earnings - Defense World
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest
H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5 - Investing.com
Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener
Fate Therapeutics (NASDAQ:FATE) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st
Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com
TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World
Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World
FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus
Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance
Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada
Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times
Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq
Fate’s FT819 shows promising results in lupus patients - Investing.com
Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan
Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):